Amisulpride
FDA-approved product (solution, intravenous), marketed as Barhemsys.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Nausea and vomiting
- Post operative nausea and vomiting
- Psychosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Benzamides
- FDA pharmacologic class
- Dopamine-2 Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Amisulpride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more44.6% AI-predicted activityagainst K. pneumoniae16 registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection44.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- TacrolimusExisting use: Atopic eczema, Delayed Graft Function, Eczematoid dermatitis and 3 more44.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more44.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more44.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Baloxavir MarboxilExisting use: Influenza, Viral disease44.0% AI-predicted activityagainst K. pneumoniae24 registered studies
- RivaroxabanExisting use: Acute coronary syndrome, Atrial fibrillation, Coronary artery disease and 9 more43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma43.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more43.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more43.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more43.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
SWitching to Abilify Trial (SWAT)
NCT00304616 · start 2004-10
Registered record
- Registry ID
- NCT00304616
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2007-10
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionAripiprazole, Solian, Olanzapine, Seroquel, RisperidonePhasePhase 4Registry statusCompletedEffect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
NCT01160991 · start 2004-05
Registered record
- Registry ID
- NCT01160991
- Conditions
- Schizophrenia; Diabetes; Insulin Resistance
- Interventions
- Glucose clamp technique; Amisulpride; Olanzapine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2006-10
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; Diabetes; Insulin ResistanceInterventionGlucose clamp technique; Amisulpride; Olanzapine; PlaceboPhaseNot applicableRegistry statusCompletedTardive Dyskinesia and Cognitive Function
NCT00926965 · start 2003-01
Registered record
- Registry ID
- NCT00926965
- Conditions
- Tardive Dyskinesia; Neurocognitive Function
- Interventions
- amisulpride; Olanzapine; Conventional antipsychotics
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-01
- Completion
- 2007-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTardive Dyskinesia; Neurocognitive FunctionInterventionamisulpride; Olanzapine; Conventional antipsychoticsPhasePhase 4Registry statusCompletedEvaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
NCT00628290 · start 2002-10
Registered record
- Registry ID
- NCT00628290
- Conditions
- Schizophrenia
- Interventions
- Cannabidiol; Amisulpride
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-10
- Completion
- 2008-03
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophreniaInterventionCannabidiol; AmisulpridePhasePhase 2Registry statusCompletedEarly Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
NCT00204061 · start 2001-01
Registered record
- Registry ID
- NCT00204061
- Conditions
- Schizophrenia; Psychoses
- Interventions
- Supportive management; Amisulpride
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-01
- Completion
- 2005-06
- Enrolment
- 124
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSchizophrenia; PsychosesInterventionSupportive management; AmisulpridePhasePhase 4Registry statusCompleted